Back to top

Image: Bigstock

Thermo Fisher Scientific, Inc.

Read MoreHide Full Article

Thermo Fisher reported a better-than-expected third-quarter 2015 with adjusted EPS and revenues exceeding the respective Zacks Consensus Estimate. However, the year-over-year top-line results were negatively affected by the impact of unfavorable foreign exchange rates. Despite that, Thermo Fisher increased its full year 2015 revenue and earnings guidance reflecting management's confidence in its operational performance as well as a robust scope for improvement despite the current challenging scenario. Thermo Fisher remains optimistic about its recent developments which include new product launches like Ion S5 and Ion S5 XL, to enable targeted next-generation sequencing; launch of immunodiagnostic tests and instruments and CE marks for clinical use of HPLC, mass spectrometry and related software.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Thermo Fisher Scientific Inc. (TMO) - free report >>

Published in